The goal of this trial is to learn if tasipimidine will help in the treatment of insomnia and how safe it is to use in sleepless people. Researchers will compare tasipimidine to a placebo (a look-alike substance that contains no drug) to see if tasipimidine works to treat insomnia. The trial consists of 2 consecutive parts and participants will be included either in Part 1 or Part 2. Part 2 will start only after Part 1 completion. Both parts include a screening period (up to 6 weeks), a treatment period (3 consecutive days and nights) and a post-treatment period (up to 10 days). Part 2 includes an additional 4 week extension part, where the participants take tasipimidine or placebo every evening at home and return to the sleep clinic for 2 last treatment nights. Participants will use equipment to record sleep parameters both at sleep clinic and home (Part 2) and a sleep diary is used.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
190
Tasipimidine solution
Tasipimidine placebo solution
Terveystalo Helsinki Uniklinikka
Helsinki, Finland
Wake after sleep onset (WASO) combined from Part 1 and Part 2
Assessed with polysomnography (PSG) for Day 1 and Day 2 data combined from Part 1 and Part 2
Time frame: Treatment Day 1 and 2
Latency to persistent sleep (LPS) combined from Part 1 and Part 2
Assessed with polysomnography (PSG) for Day 1 and Day 2 data combined from Part 1 and Part 2
Time frame: Treatment Day 1 and 2
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.